Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Angiosarcoma is a deadly cancer of endothelial cells with limited treatment options.
• Current chemotherapy offers transient responses, necessitating novel therapeutic strategies.
• Genetic analysis reveals frequent mutations in angiogenesis pathways, including VEGFR and MAPK signaling.

Purpose of the Study:

• To investigate the biological significance of VEGF and MAPK signaling in angiosarcoma.
• To evaluate the efficacy of inhibiting these pathways individually and in combination.

Main Methods:

• Immunohistochemistry used to detect active MAPK signaling (p-ERK) in clinical angiosarcoma samples.
• In vitro studies involving angiosarcoma cell lines treated with MEK inhibitor (trametinib) and VEGFR inhibitor (cediranib).
• In vivo studies using angiosarcoma xenografts and RNA sequencing to assess treatment effects.

Main Results:

• MAPK signaling was active in over half of angiosarcoma samples.
• Trametinib (MEK inhibitor) reduced angiosarcoma cell viability.
• Combined cediranib and trametinib demonstrated additive in vitro and combinatorial in vivo effects, resulting in smaller tumors.

Conclusions:

• Combined inhibition of VEGFR and MAPK pathways is a promising therapeutic strategy for angiosarcoma.
• Distinct gene expression signatures observed with combination therapy warrant further investigation.
• A clinical study of combined VEGFR and MEK inhibition in angiosarcoma is recommended.